Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
A Burchert, S Wölfl, M Schmidt… - Blood, The Journal …, 2003 - ashpublications.org
Chronic myeloid leukemia (CML) is a clonal disease of hematopoietic stem cells caused by
a reciprocal translocation of the long arms of chromosomes 9 and 22. In human leukocyte …
a reciprocal translocation of the long arms of chromosomes 9 and 22. In human leukocyte …
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
GR Angstreich, W Matsui, CA Huff… - British journal of …, 2005 - Wiley Online Library
Imatinib has impressive activity against chronic myeloid leukaemia (CML), but does not
appear to completely eradicate the disease. Although responses to interferon‐alpha (IFN) …
appear to completely eradicate the disease. Although responses to interferon‐alpha (IFN) …
[HTML][HTML] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford… - … England Journal of …, 2003 - Mass Medical Soc
Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy …
Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition
M Talpaz - Seminars in hematology, 2001 - Elsevier
The cytokine interferon-alfa (IFN-α) has substantial activity in chronic myeloid leukemia
(CML) and is the nontransplant standard of care for chronic-phase disease. When used as …
(CML) and is the nontransplant standard of care for chronic-phase disease. When used as …
[HTML][HTML] High rates of durable response are achieved with imatinib after treatment with interferon α plus cytarabine: results from the International Randomized Study of …
F Guilhot, B Druker, RA Larson, I Gathmann, C So… - …, 2009 - ncbi.nlm.nih.gov
Background Imatinib is the standard of care for newly diagnosed chronic-phase chronic
myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS …
myeloid leukemia. The largest randomized clinical trial of imatinib was the multinational IRIS …
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
H Kantarjian, C Sawyers, A Hochhaus… - … England Journal of …, 2002 - Mass Medical Soc
Background Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …
[HTML][HTML] The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic …
F Palandri, F Castagnetti, I Iacobucci, G Martinelli… - …, 2010 - ncbi.nlm.nih.gov
Before the introduction of imatinib, interferon α-based regimens were the gold standard for
treatment of early chronic phase chronic myeloid leukemia patients. The combination of IFN …
treatment of early chronic phase chronic myeloid leukemia patients. The combination of IFN …
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy
BJ Druker - European Journal of Cancer, 2002 - Elsevier
The Bcr-Abl tyrosine kinase inhibitor imatinib (Glivec®, formerly STI571, Novartis Pharma
AG, Basel, Switzerland) produces complete hematologic and cytogenetic responses in a …
AG, Basel, Switzerland) produces complete hematologic and cytogenetic responses in a …
The role of interferon-alpha in the treatment of chronic myeloid leukemia
LA Kujawski, M Talpaz - Cytokine & growth factor reviews, 2007 - Elsevier
Biological agents have long been used in the treatment of cancer, and interferon-alpha was
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …
Hematopathologic and cytogenetic findings in imatinib mesylate–treated chronic myelogenous leukemia patients: 14 months' experience
RM Braziel, TM Launder, BJ Druker… - Blood, The Journal …, 2002 - ashpublications.org
Imatinib mesylate, an Abl kinase inhibitor, produces sustained complete hematologic
responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and …
responses (CHRs) in chronic myelogenous leukemia (CML) patients, but the sequence and …